Clinical Trials Logo

Clinical Trial Summary

This study will compare stress, changes in oxygenation and oxidative damage in preterm infants with respiratory distress syndrome (RDS) randomized to receive or not remifentanil as an analgesic drug during the administration of porcine surfactant (poractant alfa, Curosurf®) through the traditional (INSURE) or the less invasive (LISA) method.


Clinical Trial Description

At present, LISA and INSURE are both used for surfactant therapy in infants as comparable methods. However, a clear policy of using analgesics during surfactant therapy is still lacking: some neonatologists use analgesics to reduce stress and pain scores, whereas others do not approve their use due to interference with spontaneous breathing.

In this open-label, randomized, phase 4 clinical trial, infants admitted to our neonatal intensive unit care (NICU) will be evaluated according to the selection criteria and then randomized to receive or not remifentanil as an analgesic drug during the administration of porcine surfactant (poractant alfa, Curosurf®) via the INSURE or LISA method: Group-1) LISA-analgesic; Group 2) LISA-no analgesic; Group-3) INSURE-analgesic; Group-4) INSURE-no analgesic. Study patients will be stratified by gestational age at birth: Block A) 23.0-27.6 weeks of gestation; Block B) 28.0-31.6 weeks of gestation.

Early caffeine administration will be provided according to our NICU guidelines shortly after birth. Infants with adequate respiratory drive will be stabilized on nasal continuous positive airway pressure (CPAP; 4-8 cm of water) right after birth. Oxygen saturation targets will be 90-94%; moderate degrees of hypercarbia (PaCO2 < 60 mmHg, provided arterial pH >7.22) will be tolerated. Conditions mimicking respiratory distress syndrome (RDS; i.e. sepsis, air leaks, aspiration pneumonia, congenital heart disease) will be ruled out. RDS diagnosis will be clinical according to the European Guidelines. Nasal CPAP, bi-level CPAP or nasal intermittent positive pressure ventilation (synchronized or not) will be used at the discretion of the attending physician to stabilize the patients. Intubation criteria according to our NICU guidelines will be:

1. severe acidosis (defined as arterial pH<7.20 with a partial pressure of carbon dioxide (PaCO2) > 55 mmHg and partial pressure of oxygen (PaO2) < 50 mmHg) with a fraction of inspired oxygen (FiO2) > 0.50;

2. severe apnoea.

Enrolled infants will be evaluated from birth to day 7 of the hospital stay. ;


Study Design


Related Conditions & MeSH terms

  • Respiratory Distress Syndrome in Premature Infants
  • Respiratory Distress Syndrome, Adult
  • Respiratory Distress Syndrome, Newborn
  • Syndrome

NCT number NCT04073173
Study type Interventional
Source Ospedali Riuniti Ancona
Contact Virgilio Carnielli, MD, PHD
Phone +390715962045
Email v.carnielli@staff.univpm.it
Status Not yet recruiting
Phase Phase 4
Start date November 1, 2020
Completion date October 31, 2022

See also
  Status Clinical Trial Phase
Completed NCT01651637 - First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome Phase 1
Terminated NCT02939742 - Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity? Phase 2/Phase 3
Completed NCT02770976 - Respiratory Pattern During Neurally Adjusted Ventilator Assist (NAVA) in Preterm Infants N/A
Completed NCT02661256 - Effect of Nasal Continuous Positive Airway Pressure on The Pharyngeal Swallow in Neonates N/A
Active, not recruiting NCT02445040 - Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW Neonates N/A
Completed NCT01962818 - High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Lung Volume Monitored by Electric Tomography Impedance. N/A
Completed NCT02210026 - Seattle-PAP Bubble Nasal CPAP and Work of Breathing Phase 1
Not yet recruiting NCT02200900 - Study of Respiratory Physiology During High Flow Nasal Cannula Treatment in Preterm Neonates. N/A
Completed NCT02396693 - Successful Extubation and Noninvasive Ventilation in Preterm ≤ 1500g Terms N/A
Completed NCT01220687 - Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation N/A